Zenuzolac - GeneOne Life Science
Alternative Names: GIT-027; GIT-27; GLS-1027; VGX-1027Latest Information Update: 06 Sep 2023
Price :
$50 *
At a glance
- Originator OncoNOX
- Developer GeneOne Life Science; Inovio Pharmaceuticals
- Class Acetic acids; Anti-inflammatories; Isoxazoles; Small molecules
- Mechanism of Action Cytokine inhibitors; Immunosuppressants; NF-kappa B inhibitors; NF-kappa B kinase inhibitors; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID-19 pneumonia
- Phase I Autoimmune disorders; Diabetic nephropathies; Inflammation; Rheumatoid arthritis; Type 1 diabetes mellitus
- Preclinical Ulcerative colitis; Uveitis
Most Recent Events
- 06 Sep 2023 Phase I development for Inflammation, Autoimmune-disorders and Diabetic-nephropathies (Prevention) is ongoing in South Korea (GeneOne Life Science pipeline, September 2023)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders in South Korea (PO)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Diabetic-nephropathies(Prevention) in South Korea (PO)